In his new role, Benecchi will lead Sage's global commercial efforts across all Sage programs, new product planning, strategy, and competitive intelligence.
Benecchi will work in collaboration with internal partners to create a shared, mission-driven, launch vision that reflects the input the company receives from external stakeholders.
Among his responsibilities will be to ensure smooth working relationships with Sage's partners and an integrated commercialization plan for zuranolone a once-daily, two-week therapy in Phase 3 clinical development for the treatment of major depressive disorder and postpartum depression.
Benecchi will also lead commercialization strategies across the company's leading portfolio of treatments for brain health disorders.
Chris Benecchi joins Sage from Alexion, where he served as vice president, Global Head of Commercial Excellence.
Previously, he spent eight years at UCB in commercial roles of increasing responsibility including Global Launch Head, Commercial and Medical Affairs, Immunology and Global Commercial Strategy Lead, Immunology.
He began his career in sales at J and J and held sales leadership and senior marketing roles at Takeda as well. Benecchi received an MBA from Duke University and a BA from Colby College.
Sage Therapeutics is a biopharmaceutical company focused on developing novel therapies for patients with debilitating disorders of the brain.
PureTech completes enrollment in Phase 2b ELEVATE IPF trial for LYT-100
Cybin secures additional US patent for CYB003 breakthrough therapy programme
UroGen's UGN-103 IND accepted by FDA for bladder cancer treatment
Biophytis reinforces obesity IP with new patent application
MaaT Pharma reveals positive 18-month data for MaaT013 in GI-aGvHD
Fusion Antibodies plc secures contract for OptiPhage library development
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients
AbbVie announces interim evaluation of Atogepant Phase three, open-label 156-week extension study
Precision Epigenomics partners with TruDiagnostic
Modalis partners with Ginkgo Bioworks
Stamford Pharmaceuticals starts locally advanced basal cell carcinoma (laBCC) trial of SP-002
Algiax Pharmaceuticals reveals update on chronic neuropathic pain study